Enhancing the anti-tumor activity of endogenous Vγ9Vδ2 T-cells against ABCB1-positive osteosarcoma, where doxorubicin fails, can be a step forward in the immune-therapy-based treatments for aggressive osteosarcomas. Here, ABCB1 is linked to osteosarcoma.